Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bright Minds BiosciencesDRUG +1.00%34 3-Year EBITDA Growth Rate is 30.70% as of Mar. 2026, which is at its 10-year median of 30.70. GuruFocus rates DRUG with a GF Scoreâ„¢ of 34/100. The stock has 1 warning sign investors should review. Among 1,135 Biotechnology companies, Bright Minds Biosciences ranks better than 68.72% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 30.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -3.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bright Minds Biosciences was 49.30% per year. The lowest was -74.30% per year. And the median was 30.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bright Minds Biosciences 3-Year EBITDA Growth Rate Related Terms
DRUG vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Bright Minds Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bright Minds Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bright Minds Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 30.70% mean?
Bright Minds Biosciences (DRUG) has a 3-Year EBITDA Growth Rate of 30.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bright Minds Biosciences and its competitors. This is near median its historical median of 30.70. According to the industry distribution chart, Bright Minds Biosciences ranks #355 out of 1135 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Bright Minds Biosciences' 3-Year EBITDA Growth Rate too high?
Bright Minds Biosciences' current 3-Year EBITDA Growth Rate of 30.70% is near median its 10-year median of 30.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Bright Minds Biosciences' value of 30.70% is 107.4% above this industry median. Based on the distribution chart, Bright Minds Biosciences ranks #355 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bright Minds Biosciences has a GF Scoreâ„¢ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #355 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Bright Minds Biosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. Bright Minds Biosciences' value of 30.70% is 107.4% above this benchmark. While the company's 10-year median is 30.70 vs. the industry median of 14.80, Bright Minds Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bright Minds Biosciences's current 3-Year EBITDA Growth Rate of 30.70% is 107.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bright Minds Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Minds Biosciences's current 3-Year EBITDA Growth Rate is 30.70%, which is near median its own 10-year median of 30.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current 3-Year EBITDA Growth Rate of 30.70%. The current 3-Year EBITDA Growth Rate is 30.70%, which is near median its 10-year median of 30.70 and 107.4% above the Biotechnology industry median of 14.80. Bright Minds Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current 3-Year EBITDA Growth Rate is 30.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score
Get the complete analysis for DRUG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRUG has been successfully added to your 
